Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Liver Cirrhosis

  Free Subscription


18.05.2026

2 BMC Gastroenterol
1 Clin Res Hepatol Gastroenterol
2 Gut
2 J Hepatol
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Gastroenterol

  1. LIAN J, Cui H, Xu B, Ye Q, et al
    A prospective cohort-based prediction model incorporating acute gastrointestinal injury for 28-day and 90-day outcomes in acute decompensation of cirrhosis.
    BMC Gastroenterol. 2026 May 14. doi: 10.1186/s12876-026-04922.
    PubMed         Abstract available

  2. WAKUI N, Ogino Y, Nagumo H, Watanabe N, et al
    Pemafibrate therapy increases serum zinc levels in patients with metabolic dysfunction-associated steatohepatitis: a prospective study.
    BMC Gastroenterol. 2026 Apr 9. doi: 10.1186/s12876-026-04806.
    PubMed         Abstract available


    Clin Res Hepatol Gastroenterol

  3. BADWEI N, El-Folly RF, Hemdan HAA, Wassif GOM, et al
    Early infection is associated with a distinct high-risk inflammatory-circulatory profile in cirrhotic patients presenting with acute upper gastrointestinal bleeding.
    Clin Res Hepatol Gastroenterol. 2026 May 11:102843.
    PubMed        


    Gut

  4. YUAN Y, Li J, Rao D, Lu X, et al
    ISG15 deficiency in hepatic stellate cells promotes TGFbeta2-induced liver fibrosis by counteracting CREB1 ISGylation.
    Gut. 2025 Aug 17:gutjnl-2025-335327. doi: 10.1136/gutjnl-2025-335327.
    PubMed         Abstract available

  5. RATZIU V, Surabattula R, Bugianesi E, Schattenberg JM, et al
    Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort.
    Gut. 2026;75:1226-1236.
    PubMed         Abstract available


    J Hepatol

  6. SILVESTER HOFER B, Tonon M, Reiberger T
    Reply to: "Early Abstinence, Socioeconomic Barriers, and Survival in Decompensated Alcohol-Related Cirrhosis: A Real-World Cohort from China".
    J Hepatol. 2026 May 12:S0168-8278(26)00278-3. doi: 10.1016/j.jhep.2026.
    PubMed        

  7. XIONG HL, Zhao Q, Liu SQ, Chen LL, et al
    Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.
    J Hepatol. 2026 May 11:S0168-8278(26)00270-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available


    PLoS One

  8. BLANCO-ECHEVARRIA A, Costa Segovia R, Guijarro Herraiz C, Garcia Izquierdo B, et al
    Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics.
    PLoS One. 2026;21:e0343134.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum